Human Papilloma Virus Testing Market Outlook 2031
The global human papilloma virus testing market size was USD 930.32 Million in 2022 and is estimated to reach USD 2.23 Billion by 2031 register a considerable CAGR 10.24% during the forecast period, 2023–2031. The growth of the market is attributed to the increasing cases of cervical cancer world-wide.
The human papillomavirus (HPV) test helps to identify human papillomavirus present in the cells, which can further develop the abnormal cervical cells or cervical cancer, and genital warts. Routine usage of the HPV test under the age of 30 years is not recommended by specialists, as it is not very helpful. HPV is a type of infection majorly occurred through sexually transmitted and very common in young people.
However, HPV infections usually get easily recovered by itself within a year or two. As per a World Health Organization report, cervical cancer is the fourth most common cancer among women. The report stated that the number of the disease cases were around 570,000 in 2018, representing 6.6% of all female cancers and the mortality rate is 90% caused by cervical cancer in underdeveloped countries.
With the increasing cases of COVID-19 all over the world in 2020, patients’ visit for numerous elective medical procedures such as cancer screening and monitoring were found subsided. One key reason for the decreasing in cancer screening adoption was due to urgent shift of pharmaceutical companies to prioritize more on essential requirements and tackle the COVID-19 pandemic.
Human Papilloma Virus Testing Market Trends, Drivers, Restraints, and Opportunities
- High mortality rate due to HPV infection and rising cases especially in developing countries are key factors that are anticipated to boost the growth of the market in the coming years.
- Shortcoming of primary screening tests such as false or negative outcome, and less sensitivity for the detection of the virus is expected to upsurge the market.
- Increasing burden of cervical cancer globally which is more commonly found in females is another factor that fuel the market growth during the forecast period.
- Constantly changing in rules & regulations related to cervical cancer screening and HPV vaccination are major obstacles affecting the growth of the HPV testing market.
- Less-skilled healthcare workers operating the diagnostic devices is one of the primary reasons that can hamper the market growth.
- Growing awareness regarding the link between HPV and cervical cancer along with the increasing demand for accurate diagnostic testing is also projected to grow the market substantially.
Scope of The Human Papilloma Virus Testing Market Report
The report on the global human papilloma virus testing market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Attributes
|
Details
|
Report Title
|
Human Papilloma Virus Testing Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
Base Year
|
2022
|
Historic Data
|
2016–2021
|
Forecast Period
|
2023–2031
|
Segmentation
|
Types (High-risk Human Papilloma Virus and Low-risk Human Papilloma Virus), Applications (Monoclonal & Polyclonal Antibodies, Immunoassays, Chromosome Analysis, Microarrays, Molecular Diagnostics, Flow Cytometry, Artificial Intelligence, Biosensors, and Microcomputers), and End-Users (Hospital & Clinics, Point of Care, and Diagnostic Centers)
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
Key Players Covered in the Report
|
Biomedical Diagnostics; Abbott; bioMerieux; CeMines, Inc; CanAG Diagnostics; Siemens Healthcare; Bio-Rad; Epigenomics; Fujirebio; Guided Therapeutics Inc; Ipsogen; Gen-Probe; J&J Diagnostics; Hologic; Polartechnics; Qiagen; Roche; Radient Pharmaceuticals; OncoLab; Sequenom; and Targeted Diagnostics & Therapeutics, Inc;
|
Human Papilloma Virus Testing Market Segment Insights
High-risk human papilloma virus segment is anticipated to hold a key market share
On the basis of types, the global human papillomavirus market is divided into high-risk human papilloma virus and low-risk human papilloma virus. The high-risk human papilloma virus segment is anticipated to hold a key market share during the forecast period owing to wide prevalence of high-risk disorders and availability of advanced diagnostic techniques for detecting the disorder.
Molecular diagnostic segment is expected to grow at a rapid pace
Based on applications, the market is segmented into monoclonal & polyclonal antibodies, immunoassays, chromosome analysis, microarrays, molecular diagnostics, flow cytometry, artificial intelligence, biosensors, and microcomputers. The molecular diagnostic segment is expected to grow at a rapid pace during the forecast period owing to the wide adoption of the diagnostic test for the detection of various types of high-risk HPV.
Molecular diagnostic tests are helpful for finding out the most appropriate diagnosis and treatments for patients. Others factors such as signal amplification, probe amplification, and target amplification in the detection and screening of HPV are expected to upsurge the market share of the segment.
Hospitals & clinics segment to register robust growth
On the basis of end-users, the global human papillomavirus market is segregated as hospital & clinics, point of care (PoC), and diagnostic centers. The hospitals & clinics segment is projected to register robust growth in the market during the forecast period as hospitals & clinics are well equipped with advanced diagnostic instruments, along with a wide availability of highly qualified medical personnel such as doctors, nurses, and technicians.
However, the PoC segment is anticipated to exhibit an impressive growth rate in the coming years due to increased demand for self-treatment and faster introduction of advanced home settings to enable simple access of patients.
North America is anticipated to constitute a key market share
In terms of regions, the global human papillomavirus testing market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to constitute a key share of the market during the forecast period.
The major factors attributing to the higher share market of the region are increasing cases of cancer and the initial stage of diagnosis and treatment awareness programs conducted by governments in the region. In addition to, governments led investments & grants have also positive impact on the growth of the HPV testing market in North America.
Meanwhile, the market of Asia Pacific is expected to grow at an impressive rate during the forecast period due to the rising prevalence of cervical cancer and sexually transmitted diseases such as HSV, and HIV, and cancroid. Advanced technology in screening assays, for determination of actual disease rather than the risk of predisposition to disease, are also projected to boost regional growth of market.
Segments
The global human papillomavirus testing market has been segmented on the basis of
Types
- High-risk Human Papilloma Virus
- Low-risk Human Papilloma Virus
Applications
- Monoclonal & Polyclonal Antibodies
- Immunoassays
- Chromosome Analysis
- Microarrays
- Molecular Diagnostics
- Flow Cytometry
- Artificial Intelligence
- Biosensors
- Microcomputers
End-Users
- Hospital & Clinics
- Point of Care
- Diagnostic Centers
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Biomedical Diagnostics
- Abbott
- bioMerieux
- CeMines, Inc.
- CanAG Diagnostics
- Siemens Healthcare
- Bio-Rad
- Epigenomics
- Fujirebio
- Guided Therapeutics Inc.
- Ipsogen
- Gen-Probe
- J&J Diagnostics
- Hologic
- Polartechnics
- Qiagen
- Roche
- Radient Pharmaceuticals
- OncoLab
- Sequenom
- Targeted Diagnostics & Therapeutics, Inc.
Competitive Landscape
Some of the major players competing in the market are Biomedical Diagnostics; Abbott; bioMerieux; CeMines, Inc; CanAG Diagnostics; Siemens Healthcare; Bio-Rad; Epigenomics; Fujirebio; Guided Therapeutics Inc; Ipsogen; Gen-Probe; J&J Diagnostics; Hologic; Polartechnics; Qiagen; Roche; Radient Pharmaceuticals; OncoLab; Sequenom; and Targeted Diagnostics & Therapeutics, Inc.
These key players are mainly focusing on organic & inorganic strategies such as merger & acquisition, approvals for products and licenses, agreements, partnerships, collaborations, and regional expansions to sustain their revenue share in the market.